Intuitive Surgical, Inc. $ISRG Position Reduced by Russell Investments Group Ltd.

Russell Investments Group Ltd. lessened its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.3% in the third quarter, HoldingsChannel.com reports. The fund owned 506,154 shares of the medical equipment provider’s stock after selling 28,143 shares during the period. Russell Investments Group Ltd.’s holdings in Intuitive Surgical were worth $206,021,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of ISRG. Bank of America Corp DE raised its holdings in shares of Intuitive Surgical by 3.3% in the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock valued at $1,667,388,000 after purchasing an additional 116,292 shares during the period. Bank of New York Mellon Corp bought a new position in Intuitive Surgical during the second quarter worth about $1,335,753,000. Amundi grew its holdings in Intuitive Surgical by 8.6% during the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after purchasing an additional 193,096 shares during the period. Arrowstreet Capital Limited Partnership increased its position in Intuitive Surgical by 95.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock worth $970,635,000 after buying an additional 1,027,475 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in Intuitive Surgical by 10.8% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,893,485 shares of the medical equipment provider’s stock worth $769,948,000 after buying an additional 184,044 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Intuitive Surgical

In related news, Director Craig H. Barratt sold 1,150 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $460.00, for a total transaction of $529,000.00. Following the sale, the director owned 1,150 shares of the company’s stock, valued at $529,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 61 shares of the business’s stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $441.60, for a total value of $26,937.60. Following the sale, the executive vice president owned 581 shares in the company, valued at $256,569.60. This represents a 9.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 39,456 shares of company stock worth $17,769,124 in the last ninety days. Insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company restated an “overweight” rating and issued a $486.00 price target (down from $487.00) on shares of Intuitive Surgical in a research note on Wednesday, October 21st. TD Cowen reaffirmed a “buy” rating and set a $485.00 price objective on shares of Intuitive Surgical in a research report on Monday, October 19th. Wall Street Zen upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Raymond James Financial reiterated an “outperform” rating and issued a $480.00 price objective on shares of Intuitive Surgical in a report on Wednesday, October 21st. Finally, Stifel Nicolaus dropped their price objective on shares of Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating on the stock in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $493.54.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $439.89 on Friday. The business has a fifty day moving average price of $416.12 and a two-hundred day moving average price of $430.38. Intuitive Surgical, Inc. has a fifty-two week low of $328.57 and a fifty-two week high of $603.88. The stock has a market capitalization of $152.48 billion, a PE ratio of 53.19, a PEG ratio of 3.10 and a beta of 1.45.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.35. The company had revenue of $3.05 billion for the quarter, compared to analyst estimates of $2.91 billion. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The company’s revenue for the quarter was up 21.7% compared to the same quarter last year. During the same quarter last year, the company posted $2.40 EPS. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.